The Company does not have any formal policies regarding the timing of awards of options in relation to the disclosure of material nonpublic information by the Company. However, it has implemented a practice of timing grants of equity awards within an open trading window, wherever possible, in order to avoid conflicts. The Company’s historical practice has been to make annual grants of equity awards, including options, mid-August of each year, following the release of the Company’s financial results for its prior fiscal year. As a result, these grants typically are made at a time when possession of material nonpublic information is less likely and after year-end financial results have been released to the market. However, during fiscal year 2026, certain option grants were made within the period starting four business days before the Company filed a Form 10-K, Form 10-Q, or Form 8-K with the SEC and ending one business day after the filing. As a result, the Company is disclosing the following information regarding the change in the Company’s stock price between the trading day ending immediately before the SEC filing and the trading day beginning immediately following the SEC filing.

(¹) On August 15, 2025, Mr. Nassif, Mr. Naemura, and Dr. Rocklin were granted options as part of the annual grant one day after the Company filed a Form 8-K on August 14, 2025. The Company filed a Form 8-K on August 14, 2025 to disclose the retirement of a director and the appointment of a new director. To the extent this constituted material nonpublic information, the percentage change in the stock price required to be disclosed by this table is (1.99)%. In addition, a Form 8-K was filed August 21, 2025, to disclose the Company’s grant of certain equity awards to executive officers on August 15, 2025. To the extent this constituted material nonpublic information, the percentage change in the stock price required to be disclosed by this table is 1.26%.

(²) On January 7, 2026, Dr. Ranalli was granted a special new hire inducement award one day before the Company filed a Form 8-K on January 8, 2026. The grant was aligned to her hire date of January 7, 2026, which was negotiated at the end of calendar year 2025. The Form 8-K filed January 8, 2026 disclosed the release of results of operations for the Company’s fiscal year 2026 second quarter ended November 30, 2025. The percentage change in the stock price required to be disclosed by this table is 30.35%.

(³) On June 2, 2025, Mr. Naemura and Dr. Rocklin were granted a special retention grant comprised of stock options and RSUs two business days before the Company filed a Form 8-K on June 4, 2025 to disclose a financial presentation for the William Blair Growth Stock Conference. To the extent this constituted material nonpublic information, the percentage change in the stock price required to be disclosed by this table is (18.7)%.